PHGE | tickerfilter.com

Fundamental analysis

18%

Profitability 22%

Dept financing 16%

Liquidity 15%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-3.89%

1 Month

17.38%

3 Months

-23.75%

6 Months

117.50%

1 Year

195.45%

2 Year

212.68%

Key data

Stock price

$0.71

P/E Ratio

0.00

DAY RANGE

$0.71 - $0.79

EPS

$0.00

52 WEEK RANGE

$0.15 - $1.62

52 WEEK CHANGE

$214.81

MARKET CAP

7.120 M

YIELD

N/A

SHARES OUTSTANDING

178.958 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

$139,846

AVERAGE 30 VOLUME

$106,897

Company detail

CEO: Jonathan E. Solomon
Region: US
Website: biomx.com
Employees: 120
IPO year: 2019

Issue type: Common Stock
Market: NYSE American
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

BiomX Inc. develops products using natural and engineered phage technologies to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC) The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S.Aureus), a bacteria associated

PHGE - BiomX Inc.